

2

TPI-T100XC1
Serial No. 09/628,667

In the Claims

Claims 1-29 (Canceled)

Claim 30 (Currently Amended): A method for testing solubility of an active pharmaceutical ingredient in a sample, comprising:

- (a) preparing an array comprising 1000 or more samples, each sample comprising less than about 100 mg of the active pharmaceutical ingredient and at least three excipients, wherein each sample differs from any other sample with respect to at least one of:
 - (i) the identity of an excipient, or
 - (ii) the ratio of the active pharmaceutical ingredient to the excipient;
- (b) testing the 1000 or more samples for solubility of the active pharmaceutical ingredient in each sample; and
- (c) comparing the solubilities of each sample to a baseline or a control for the solubility to generate a comparison result for each sample;

wherein said active pharmaceutical ingredient has low water solubility ~~is griseovulvin~~ and wherein at least one sample has decreased solubility and at least one sample has a synergistic increased solubility.

Claims 31-32 (Canceled)

Claim 33 (Previously presented): The method of claim 30, further comprising generating of a data set from the samples.

Claim 34 (Previously presented): The method of claim 30, wherein preparing the array and testing the samples is performed by an automated sample preparation and testing system.

Claim 35 (Previously presented): The method of claim 33, further comprising analyzing the

J:\TPI-T100XC1\Pre-Amdt.doc/DNB/fce

3

TPI-T100XC1
Serial No. 09/628,667

data set by a computer.

Claim 36 (Canceled)

Claim 37 (Previously amended): The method of claim 30, wherein an amount of the active pharmaceutical ingredient is less than about 1 milligram.

Claim 38 (Previously amended): The method of claim 30, wherein an amount of the active pharmaceutical ingredient is less than about 100 micrograms.

Claim 39 (Previously amended): The method of claim 30, wherein an amount of the active pharmaceutical ingredient is less than about 100 nanograms.

Claims 40-42 (Canceled)

Claim 43 (Previously presented): The method of claim 30, wherein at least 1000 samples are tested per day.

Claims 44-129 (Canceled)

Claim 130 (New): The method according to claim 30, wherein said active pharmaceutical ingredient is: a cardiovascular pharmaceutical, an anti-infective, a gastrointestinal product, a respiratory therapeutic agent, a cholesterol reducer, a cancer or cancer-related therapeutic, a blood modifier, an anti-arthritis, AIDS, or AIDS-related therapeutic agent, hormones, biologicals, diabetes and diabetes-related agents, analgesics, anesthetics, anti-migraine, a sedative or hypnotic, an imaging component, or a diagnostic and contrast agent.

Claim 131 (New): The method according to claim 30, wherein said at least three excipients are selected from the group consisting of: acidulents; solubilizing components; absorbents; alkalizing

JATPNT100XC1\Pre-Amdt.doc/DNB/fcc

components; anticaking components; antimicrobial components; antioxidants; binders; buffering components; chelating components; coating components; controlled release vehicles; detergents; emollients; emulsifying components; flavoring components; humectants; lubricants; solvents; stabilizing components; tonicity components; binders; fillers; and mixtures thereof.

Claim 132 (New): The method according to claim 30, wherein said active pharmaceutical ingredient is cyclosporin.

Claim 133 (New): The method according to claim 30, wherein said active pharmaceutical ingredient is paclitaxel.

Claim 134 (New): The method according to claim 30, wherein said active pharmaceutical ingredient is sildenafil citrate.

Claim 135 (New): The method according to claim 30, wherein said active pharmaceutical ingredient is saquinavir.